Form 4: Coherus Oncology Director Mats Wahlstrom Granted 112,000 Stock Options

Coherus Oncology, Inc. Director Mats Wahlstrom was granted 112,000 stock options with an exercise price of $0.7904, vesting one year from June 11, 2025.

Summary

• Mats Wahlstrom, a Director at Coherus Oncology, Inc. (CHRS), was granted 112,000 stock options.
• The transaction date for this grant was June 12, 2025.
• Each option has an exercise price of $0.7904.
• The options will vest and become exercisable as to 100% of the total number of shares on the one-year anniversary of June 11, 2025, which is June 11, 2026.
• Vesting is contingent upon Mr. Wahlstrom's continued service relationship with Coherus Oncology, Inc. on the vesting date.
• The options have an expiration date of June 12, 2035.
• Following this transaction, Mats Wahlstrom directly beneficially owns 112,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the option grant aligns the director's interests with shareholders, which is generally viewed favorably, though it's a routine compensation event.

Positives

• The grant of stock options aligns the interests of Director Mats Wahlstrom with those of the shareholders, as his compensation is tied to the company's future stock performance.
• Equity compensation is a standard practice to attract and retain qualified directors and incentivize long-term value creation.

Future Outlook

The stock options granted to Director Mats Wahlstrom are scheduled to vest 100% on June 11, 2026, provided his service relationship with Coherus Oncology, Inc. continues until that date.

Industry Context

This Form 4 filing reports a routine equity compensation grant to a director, which is a common practice across the biotechnology and pharmaceutical industries to incentivize leadership and align their interests with long-term company performance.

Related Party Transactions

• The grant of 112,000 stock options to Mats Wahlstrom, a Director, represents a transaction between the company and a related party (an insider) as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant of options could lead to potential future dilution if exercised, but also aims to align the director's incentives with shareholder value creation.
• Director (Mats Wahlstrom): Receives equity compensation, providing a direct financial interest in the company's stock performance.

Next Steps

• The stock options are expected to vest on June 11, 2026, subject to the director's continued service.

Key Dates

Keywords

Coherus Oncology, CHRS, SEC Form 4, Insider Transaction, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership